Condition: AML · MDS · Sponsor: TScan Therapeutics, Inc.
This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The study will compare TSC-101 plus standard of care (SOC) versus SOC alone in participants undergoing allogeneic peripheral blood stem cell transplantation from haploidentical or mismatched unrelated donors.
This description comes directly from the study's public registry record.
Marlyane Motta · (857) 399-9887 · mmotta@tscan.com
Always discuss trial participation with your own doctor first.
| Banner Health - MD Anderson Cancer Center | Gilbert, Arizona, United States | Not Yet Recruiting |
| Honor Health Cancer Transplant Institute | Scottsdale, Arizona, United States | Not Yet Recruiting |
| City of Hope | Duarte, California, United States | Recruiting |
| Stanford - School of Medicine | Stanford, California, United States | Not Yet Recruiting |
| University of Colorado - Anschutz Cancer Center | Aurora, Colorado, United States | Recruiting |
| SCRI - Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Yale | New Haven, Connecticut, United States | Recruiting |
| Memorial Cancer Institute | Hollywood, Florida, United States | Recruiting |
| Moffitt Cancer Institute | Tampa, Florida, United States | Recruiting |
| Northside Hospital | Atlanta, Georgia, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Not Yet Recruiting |
| The University of Kansas Cancer Center | Kansas City, Kansas, United States | Not Yet Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07702578